Net sales rose 43% year-over-year to SEK 4.5 million, with operating loss halved and strong equity ratio. Strategic financing and regulatory milestones support accelerated commercialization in neurosurgery.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.